Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
Kintara Therapeutics (Nasdaq: KTRA) will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. President and CEO Robert Hoffman will deliver a corporate overview available on March 28 at 9:00 a.m. ET. The company focuses on developing innovative cancer therapies with two late-stage candidates: VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer. Kintara aims to address unmet medical needs through these therapeutics.
- None.
- None.
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that President and CEO Robert Hoffman will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held on March 28-30, 2022.
Mr. Hoffman will present a corporate overview which will become available on Monday, March 28, 2022 at 9:00 a.m. ET.
Investors can view the presentation by registering for the conference here and also request a one-on-one meeting with management to be arranged following the conclusion of the conference.
About Kintara
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the GBM AGILE study to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-maxim-group-2022-virtual-growth-conference-301507493.html
SOURCE Kintara Therapeutics
FAQ
When will Kintara Therapeutics present at the Maxim Group 2022 Virtual Growth Conference?
Who is the CEO of Kintara Therapeutics?
What two therapies is Kintara Therapeutics developing?
What is the focus of Kintara Therapeutics?
